GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study
- Conditions
- Thoracoabdominal Aortic AneurysmPararenal Aortic AneurysmAbdominal Aortic Aneurysm
- Interventions
- Device: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
- Registration Number
- NCT06578741
- Lead Sponsor
- W.L.Gore & Associates
- Brief Summary
This study aims to confirm that the benefit-risk assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) remains positive in real-world use and to ensure the adequacy of the TAMBE Device training program.
- Detailed Description
A maximum of 300 adult subjects will be enrolled at up to 60 U.S. centers, with a minimum of 70 subjects enrolled at study centers with no prior experience using the TAMBE Device. Subjects will have follow-up at 1 month, 6 months, 12 months and annually thereafter through 10 years post implant.
Recruitment & Eligibility
- Status
- ENROLLING_BY_INVITATION
- Sex
- All
- Target Recruitment
- 300
The subject is / has:
- Treated with the aortic component of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Aortic Component) to allow endovascular repair of an aortic disease involving the visceral vessels.
- Age ≥18 years at the time of informed consent signature.
- An Informed Consent Form signed by subject or legal representative.
The subject is / has:
- Any contraindications for the TAMBE Device according to the IFU.
- Planned parallel grafting with the TAMBE Aortic Component.
- Intent to modify TAMBE Aortic Component (e.g., in situ fenestration).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Single Arm GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device) Treatment with GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
- Primary Outcome Measures
Name Time Method Co-Primary Endpoint #2: Clinical Success Index procedure through 12 months All of the following qualifying criteria are met from the initiation of the index procedure through 12 months post-index procedure:
* Technical success
* Absence of death from the initial procedure, secondary intervention, or aorta-related cause
* Absence of persistent type I or type III endoleak
* Absence of lesion enlargement \>5 mm
* Absence of device migration \>10 mm
* Absence of failure due to device integrity issues (defined as Grade 2 or 3 in Table 8)
* Absence of lesion rupture
* Absence of conversion to open surgical repair
* Absence of permanent paraplegia (see definition below)
* Absence of disabling stroke (see definition below)
* Absence of "loss of function" or "end-stage renal disease" stage according to the RIFLE Classification following the index procedureCo-Primary Endpoint #1: Technical Success Time of index procedure All of the qualifying criteria are met (in the absence of surgical conversion or mortality, type I or type III endoleak, branch occlusion, or graft limb obstruction):
* Successful access to the arterial system using remote arterial exposure, percutaneous technique, or open surgical conduits at index procedure.
* Successful delivery and deployment of the aortic stent graft and all modular stent graft components at index procedure
* Successful side branch catheterization and placement of bridging stents with restoration and maintenance of flow in all intended target vessels at final completion angiography.
* Absence of type I or type III endoleaks at final completion angiography.
* Patency of all aortic modular stent graft components and intended side branch components at final completion angiography.
- Secondary Outcome Measures
Name Time Method Secondary Patency 30 days, 6 months, annually through 10 years Endovascular restoration of patency after occlusion of the side branch, stent, or stent graft has already occurred.
Note: Conversion to bypass or inability to treat by endovascular means defines loss of secondary patency.Target Vessel Technical Success 30 days, 6 months, annually through 10 years Successful catheterization and stent placement in all intended target vessels. Note: For this study, technical success will be reported for the overall procedure and specifically for the vessels targeted for treatment with the branch components (this "target vessel technical success" definition).
Intraprocedural Complications 30 days, 6 months, annually through 10 years Any vessel perforation, dissection, or occlusion during target vessel cannulation and/or stenting.
Secondary Clinical Success 30 days, 6 months, annually through 10 years Initial clinical success that is interrupted by a treatment failure and is successfully corrected with secondary reintervention (e.g., a patient undergoes a successful treatment of a type I, II, or III endoleak).
Thirty-Day Mortality 30 days Any death that occurs during the procedure, within the index procedure hospital stay, or within the first 30 days post-index procedure.
Target Vessel Instability 30 days, 6 months, annually through 10 years Any death or rupture related to side branch complication (e.g., endoleak) or any secondary intervention indicated to treat a branch-related complication, including endoleak, disconnection, kink, stenosis, occlusion, or rupture.
Assisted Primary Clinical Success 30 days, 6 months, annually through 10 years Clinical success that is obtained initially and continuously maintained with additional secondary reinterventions thus no interruption to initial clinical success.
Lesion-Related Mortality 30 days, 6 months, annually through 10 years Any death that occurs within the first 30 days, or any death that results from lesion rupture, aorta-related complications (e.g., infection, occlusion, dissection, hematoma), or a complication of a secondary intervention.
Major Adverse Events (MAEs) 30 days, 6 months, annually through 10 years Includes any of the following:
* All-cause mortality;
* Myocardial infarction resulting in severe hemodynamic dysfunction necessitating resuscitation, cardiac arrest, or fatal outcome;
* Respiratory failure requiring prolonged (\>24 hours from anticipated) mechanical ventilation or reintubation;
* Renal function decline characterized by one or more of the following:
* \>50% reduction in baseline Estimated Glomerular Filtration Rate (eGFR); or,
* New-onset dialysis;
* Bowel ischemia requiring surgical resection or not resolving with medical therapy;
* Permanent paraplegia (see "permanent paraplegia" definition below)
* Any major strokePrimary Patency 30 days, 6 months, annually through 10 years Uninterrupted patency with no occlusion or procedure performed to maintain patency on the stent or native target vessel.
Note: Interventions intended to treat endoleak or stent disconnection do not count as loss of primary patency.Secondary interventions Time of index procedure Any Reintervention: Any repeated vascular or nonvascular procedure on the index device (TAMBE Device or any stent or stent graft in contact with any TAMBE component).
• Note: Reintervention will be classified as "major", "minor", or "nonvascular" based on the definitions below.
Major Reintervention: Deployment of proximal or distal extensions, removal of the device, use of thrombectomy or thrombolysis, and any major open surgical procedure.
Minor Reintervention: Endovascular procedures (percutaneous transluminal angioplasty, atherectomy, stenting) without thrombectomy or thrombolysis, interventions to treat branch vessel stenosis, interventions to treat type II endoleaks or branch-related endoleaks, and minor surgical revisions (patch angioplasty) of the access vessels.
Nonvascular Reinterventions: Any reinterventions that would not be considered "major reintervention" or "minor reintervention" based on the above definitions.Kink 30 days, 6 months, annually through 10 years Objective documentation of demonstrable angulation (localized angle of less than 90 degrees when measured along the centerline) in any of the stent components or native target vessel
Stenosis 30 days, 6 months, annually through 10 years Objective documentation of presence of narrowing with demonstrable flow in any of the components
Occlusion 30 days, 6 months, annually through 10 years Objective documentation of presence of complete stent occlusion with or without minimal flow into a targeted vessel.
Note: Occlusions will be stated if they occurred in the aortic component, in a branch component, or in a contralateral leg component used to treat the aortic disease.Primary Assisted Patency 30 days, 6 months, annually through 10 years Endovascular intervention performed to maintain patency in the presence of stenosis before occlusion.
Trial Locations
- Locations (1)
Stanford Hospital
🇺🇸Stanford, California, United States